Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.
1. A pharmaceutical composition comprising:
a purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, wherein said purified polysulfated glycosaminoglycan includes no more than 10 wt % of carbohydrates or other contaminants with a molecular weight below 1,000 Daltons;
a skin penetrating agent, wherein said skin penetrating agent promotes transdermal penetration of said polysulfated glycosaminoglycan when applied to intact skin surfaces; and
a pharmaceutical carrier for topical application, said pharmaceutical carrier being mixed with said polysulfated glycosaminoglycan and said skin penetrating agent.
2. The pharmaceutical composition of claim 1 , wherein said purified polysulfated glycosaminoglycan has an average molecular weight ranging from 7,000 to 9,500 Daltons.
3. The pharmaceutical composition of claim 1 , wherein said purified polysulfated glycosaminoglycan contains less than 5,000 ppm of acetic acid.
4. The pharmaceutical of claim 1 , wherein said purified polysulfated glycosaminoglycan contains less than 5,000 ppm of acetic acid after storage at room temperature for at least 12 months following initiation of storage.
5. The pharmaceutical composition of claim 1 , wherein said purified polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 6 months following initiation of storage.
6. The pharmaceutical composition of claim 1 , wherein said purified polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 12 months following initiation of storage.
7. The pharmaceutical composition of claim 1 , wherein
said purified polysulfated glycosaminoglycan is prepared by a process comprising subjecting a polysulfated glycosaminoglycan starting material containing components above 1,000 Daltons and below 1,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 1,000 Daltons in the starting material to produce said purified polysulfated glycosaminoglycan.
8. The pharmaceutical composition of claim 1 , wherein said skin penetrating agent is selected from the group consisting of acetone, acyl lactylates, acyl peptides, acylsarcosinates, alkanolamine salts of fatty acids, alkyl benzene sulphonates, alkyl ether sulphates, alkyl sulphates, anionic surface-active agents, benzyl benzoate, benzyl salicylate, butan-1,4-diol, butyl benzoate, butyl laurate, butyl myristate, butyl stearate, cationic surface-active agents, citric acid, cocoamidopropylbetaine, decyl methyl sulfoxide, decyl oleate, dibutyl azelate, dibutyl phthalate, dibenzyl sebacate, dibutyl sebacate, dibutyl suberate, dibutyl succinate, dicapryl adipate, didecyl phthalate, diethylene glycol, diethyl sebacate, diethyl-m-toluamide, di(2-hydroxypropyl)ether, diisopropyl adipate, diisopropyl sebacate, N,N-dimethyl acetamide, dimethyl azelate, N,N-dimethyl formamide, 1,5-dimethyl-2-pyrrolidone, dimethyl sebacate, dimethyl sulfoxide, dioctyl adipate, dioctyl azelate, dioctyl sebacate, 1,4 dioxane, 1-dodecylazacyloheptan-2-one, dodecyl dimethyl amine oxides, ethyl caprate, ethyl caproate, ethyl caprylate, 2-ethyl-hexyl pelargonate, ethyl-2-hydroxypropanoate, ethyl laurate, ethyl myristate, 1-ethyl-2-pyrrolidone, ethyl salicylate, hexyllaurate, 2-hydroxyoctanoic acid, 2-hydroxypropanoic acid, 2-hydroxypropionic acid, isothionates, isopropyl isostearate, isopropyl palmitate, guar hydroxypropyltrimonium chloride, hexan-2,5-diol, khellin, lamepons, lauryl alcohol, maypons, metal salts of fatty acids, methyl nicotinate, 2-methylpropan-2-ol, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, methyl taurides, miranol surfactants, nonionic surface-active agents, octyl alcohol, octylphenoxy polyethoxyethanol, oleic acid, ethanolamide, oleyl alcohol, pentan-2,4-diol, phenoxyethanol, phosphatidyl choline, phosphine oxides, polyalkoxylated ether glycollates, poly(diallylpiperidinium chloride), poly(dipropyldiallyl ammonium chloride), polyglycerol esters, polyoxyethylene lauryl ether, polyoxy:polyoxyethylene stearate, polyoxypropylene 15 Stearyl ether, poly(vinyl pyridinium chloride), propan-1-ol, propan-2-ol, propylene glycol dipelargonate, pyroglutamic acids, 2-pyrrolidone, pyruvic acids, Quaternium 5, Quaternium 18, Quaternium 19, Quaternium 23, Quaternium 31, Quaternium 40, Quaternium 57, quartenary amine salts, quaternized poly (dimethylaminoethylmethacrylate), quaternized poly (vinyl alcohol), Sapamin hydrochloride, sodium cocaminopropionate, sodium dioctyl sulfosuccinate, sodium laurate, sodium lauryl ether sulfate, sodium lauryl sulfate, sugar esters, sulphosuccinate, tetrahydrofuran, tetrahydrofurfural alcohol, transcutol, triethanolamine dodecyl benzene sulphonate, triethanolamine oleate, salts, essential oils and their terpene components, vegetable carrier oils, emulsifiers, ethanol, dimethyl sulfoxide, dimethyl isosorbide, isopropyl myristate, propylene glycol, sodium lauryl sulfate, lauryl amine oxide, vitamin E, lower alcohols, iso-forms of alcohols, aliphatic diols and triols, urea or other amide derivatives, primary and secondary alcohols, fatty acids, fatty acid esters, polyols, amides, surfactants, terpenes and terpenoids, alkanones, organic acids and esters, cyclodextrins, phospholipids, and combinations thereof.
9. The pharmaceutical composition of claim 1 , wherein said skin penetrating agent is selected from the group consisting of primary or secondary alcohols, polyoxy ethers of fatty acids, vitamins, antioxidants, antimicrobial preservatives, fatty acid esters, and combinations thereof.
10. The pharmaceutical composition of claim 1 further comprising a pharmaceutically active agent.
11. The pharmaceutical composition of claim 10 , wherein said pharmaceutically active agent is selected from the group consisting of pharmaceutically acceptable free bases, salts, esters, ethers, or solvates of antibiotics, anti-infectives, antimycotics agents, steroids, cannabinoids, antihistamines, anti-inflammatory agents, antiparasitic agents, immunomodulators, antisense agents, antiviral agents, treatments for hyper- and hypo skin pigmentation disorders, anti-psoriatic agents, keratolytic agents, DNA synthesis inhibitors, cytotoxic agents, antithyroid agents, monoclonal antibody regulators, TNF alpha antagonists, immunoglobulins, metabolic regulators, antiangiogenic agents, protease inhibitors, anxiolytics, kinase regulators, cell growth regulators, enzymes, prostaglandins, peptides, analgesics, skin moisturizers, astringents, exfoliating agents, agents intended to protect the skin or modify its appearance or improve its rate of healing, anesthetic agents, and combinations thereof.
12. The pharmaceutical composition of claim 1 further comprising:
an additive selected from the group consisting of adjuvants, gelling agents, thickeners, solvents, preservatives, pH modifiers, colorants, perfumes, flavors, propellants, absorbents, adsorbents, antioxidants, antimicrobial preservatives, and combinations thereof.
13. The pharmaceutical composition of claim 1 , wherein said carrier is selected from the group consisting of a transdermal tape, a transdermal patch, an ointment, a cream, a gel, a paste, a collodion composition, a foam, a rapid dissolving solid, and a lotion.
14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 0.1 to 25 wt % of said polysulfated glycosaminoglycan, 20 to 60 wt % of said skin penetrating agent, and 20 to 80 wt % of said carrier.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 5 to 16 wt % of said polysulfated glycosaminoglycan, 25 to 55 wt % of said skin penetrating agent, and 25 to 75 wt % of said carrier.
16. The pharmaceutical composition of claim 1 , wherein said composition is in a form suitable for topical application to skin.
17. The pharmaceutical composition of claim 16 , wherein said skin penetrating agent is an oil-in-water emulsion comprising one or more of tocopherol acetate, an aloe derivative, a silicon derivative, a chelating agent, an emulsifier, and a polyol.
18. The pharmaceutical composition of claim 1 , wherein said composition is in a form suitable for topical application to mucosa.
19. The pharmaceutical composition of claim 1 , wherein said composition is in a form suitable for delivery by aural, oral, ophthalmic, nasal, rectal, urethral, vaginal, dermal, buccal, or sublingual routes.
20. The pharmaceutical composition of claim 1 , wherein said composition is in the form of an aerosol, a chewable bar, a bead, a capsule, a cellular sheet, a chewable gel, a concentrate, a cream, an elixir, an emulsion, an enema, a film, a gel, a chewing gum, an irrigant, a jelly, a liniment, a lipstick, a liquid, a lotion, a lozenge, a mouthwash, an oil, an ointment, a paste, a pastille, a patch, a pellet, a pill, a plaster, a poultice, a powder, a ring, a rinse, a salve, a shampoo, a soap, a solution, a sponge, a spray, a stick, a strip, a suppository, a suspension, a swab, a syrup, a tablet, a tampon, a tape, a tincture, a troche, a wafer, and/or combinations thereof.
21. The pharmaceutical composition of claim 1 , wherein said skin penetrating agent is an emulsion.
22. A pharmaceutical composition comprising:
a purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, wherein said purified polysulfated glycosaminoglycan includes no more than 20 wt % of carbohydrates or other contaminants with a molecular weight below 3,000 Daltons;
a skin penetrating agent, wherein said skin penetrating agent promotes transdermal penetration of said polysulfated glycosaminoglycan when applied to intact skin surfaces; and
a pharmaceutical carrier for topical application, said pharmaceutical carrier being mixed with said polysulfated glycosaminoglycan and said skin penetrating agent.
23. The pharmaceutical composition of claim 22 , wherein said purified polysulfated glycosaminoglycan is prepared by a process comprising subjecting a polysulfated glycosaminoglycan starting material containing components above 3,000 Daltons and below 3,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 3,000 Daltons in the starting material to produce said purified polysulfated glycosaminoglycan.
24. The pharmaceutical composition of claim 22 , wherein said purified polysulfated glycosaminoglycan has an average molecular weight ranging from 7,000 to 9,500 Daltons.
25. A pharmaceutical composition comprising:
a purified polysulfated glycosaminoglycan having an average molecular weight ranging from 5,000 to 15,000 Daltons, wherein said purified polysulfated glycosaminoglycan includes no more than 25 wt % of carbohydrates or other contaminants with a molecular weight below 5,000 Daltons;
a skin penetrating agent, wherein said skin penetrating agent promotes transdermal penetration of said polysulfated glycosaminoglycan when applied to intact skin surfaces; and
a pharmaceutical carrier for topical application, said pharmaceutical carrier being mixed with said polysulfated glycosaminoglycan and said skin penetrating agent.
26. The pharmaceutical composition of claim 25 , wherein said purified polysulfated glycosaminoglycan is prepared by a process comprising
subjecting a polysulfated glycosaminoglycan starting material containing components above 5,000 Daltons and below 5,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 5,000 Daltons in the starting material to produce said purified polysulfated glycosaminoglycan, wherein said purified polysulfated glycosaminoglycan has an average molecular weight ranging from 5,000 to 15,000 Daltons.
27. The pharmaceutical composition of claim 25 , wherein said purified polysulfated glycosaminoglycan has an average molecular weight ranging from 7,000 to 9,500 Daltons.